20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ:NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) application for its Neuro-Spinal Scaffold implant.
- Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions.
- The FDA previously approved the review process for the Neuro-Spinal Scaffold implant, which includes three modules: Preclinical studies module, manufacturing module, and clinical data module.
- InVivo is actively enrolling patients with acute spinal cord injury into its INSPIRE 2.0 study, a pivotal trial of the Neuro-Spinal Scaffold.
- The 20-patient trial is designed to expand upon the existing clinical evidence for the Neuro-Spinal Scaffold from the Company's INSPIRE 1.0 study.
- Price Action: NVIV shares are up 16.7% at $0.79 during the premarket session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!